Clinical Trial Search

Primary: Percentage of Participants Achieving Endoscopic Response at Week 12 — 10.9; 25.8; 37.5; 43.8 percentage of participants — p=0.079

Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants

Primary: Number of Patients With Adverse Events During and After FMT — 1 Participants

Primary: The Number of Participants Experiencing Adverse Events (AE) — 11 Participants

Primary: Objective Response in Bone From Time of Initiation of Therapy to > 6 Months — 8; 7 Participants

Primary: Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events — 0.142; 0.142; 0.142; 0.142 proportion of participants

Primary: High or Medium (Versus Low) Mediterranean Diet Adherence — 55.99; 50.53 percentage of arm

Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants

Primary: Safety as Measured by Adverse Events Frequencies (by Type and Severity) — 174; 355; 0; 1 events

Primary: Number of Participants Who Had a Pathological Complete Response (pCR) — 0; 3 Participants

Primary: Number of Participants With Sustained Return of Spontaneous Circulation — 37; 53 Participants

Primary: Major Pathological Response Rate — 11.1; 19.0; 30.0; 31.3 Percentage of participants

Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale

Primary: Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC) — 0; 0 Participants

Primary: Best Overall Response Rate — 5 percentage of participants